BCDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioCardia Inc (BCDA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, the financial performance is weak with declining net income and EPS, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. Holding off on investing in this stock is recommended until there are clearer signs of improvement in financials or technical trends.
The technical indicators for BCDA are bearish. The MACD is negative and expanding downward, RSI is neutral at 35.735, and moving averages are aligned bearishly (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot point of 1.208, with key support at 1.116 and resistance at 1.3.
Insiders are buying, with a 373.20% increase in insider buying over the last month. Additionally, the company has completed its FDA pre-submission for the Helix catheter, which could enhance its market position in cardiovascular disease treatment.
The company's financial performance is weak, with no revenue growth, a significant drop in net income (-14.62% YoY), EPS (-60.66% YoY), and gross margin (-100% YoY). Technical indicators are bearish, and there are no recent trading signals or significant trading trends from hedge funds.
In Q3 2025, the company reported no revenue growth, a decline in net income to -1,483,000 (-14.62% YoY), a significant drop in EPS to -0.24 (-60.66% YoY), and a gross margin of 0 (-100% YoY).
No analyst rating or price target data is available for BCDA at this time.
